Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 523Leukemia, Myeloid, Acute 499Neoplasms 381Carcinoma, Non-Small-Cell Lung 381Pancreatic Neoplasms 329Precursor Cell Lymphoblastic Leukemia-Lymphoma 319Multiple Myeloma 312Glioblastoma 311Melanoma 310Prostatic Neoplasms 293Leukemia 289Neoplasm Metastasis 284Brain Neoplasms 277Lymphoma 271Lung Neoplasms 270Recurrence 267Ovarian Neoplasms 247Colorectal Neoplasms 246Lymphoma, Non-Hodgkin 242Leukemia, Lymphocytic, Chronic, B-Cell 231Glioma 209Myelodysplastic Syndromes 208Lymphoma, Large B-Cell, Diffuse 186Carcinoma, Hepatocellular 173Lymphoma, Follicular 167Head and Neck Neoplasms 162Hodgkin Disease 160Lymphoma, Mantle-Cell 155Burkitt Lymphoma 154Sarcoma 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Plasmablastic Lymphoma × Clear all
NCT07113496 2025-08-13

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

The First Affiliated Hospital with Nanjing Medical University

Phase 1 Not yet recruiting
27 enrolled
LymphoidPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡